HK Stock Market Move | Intraday, JingTai Technology (02228) rose nearly 5%, empowering Lyming Biotech to achieve significant results in cell therapy. Clinical trials in multiple solid tumor areas will be initiated.

Crystal Technologies (02228) rose nearly 5% during trading. As of the time of writing, it had risen by 3.88% to 13.4 Hong Kong dollars, with a turnover of 5.96 billion Hong Kong dollars. On the news front, recently, Crystal Technologies incubated enterprise Lamon Bio presented at the 44th JP Morgan Healthcare Conference and showcased the latest results of the investigator-initiated clinical trials (IIT) of its ultra-low dose CAR-T therapy to global investors. With the research and development support from Crystal Technologies, Lamon Bio has developed multiple research pipelines based on its AI+ Immune Metabolism Reprogramming platform. Among them, the metabolism-enhanced CD19 CAR-T therapy has achieved complete remission and discharge for several patients with systemic lupus erythematosus at a dosage one thousandth of the conventional CAR-T treatment, demonstrating a new possibility for future "outpatient" CAR-T therapy. Additionally, this therapy has helped dozens of relapsed and refractory leukemia/lymphoma patients achieve complete remission, and multiple IIT clinical trials in the field of solid tumors are currently underway or about to start. It is worth mentioning that Crystal Technologies has collaborated with Lamon Bio to develop the META 10-AI platform. By combining Crystal Technologies' AI algorithms with high-throughput screening experiments, the core metabolic enhancers used in the metabolism-enhanced CAR-T therapy have been optimized to increase their affinity by hundreds of times. The relevant results have been applied for a Chinese patent and are being used in the research and development of metabolism-enhanced CAR-T pipelines targeting solid tumors, significantly enhancing the anti-exhaustion capacity of CAR-T cells in the solid tumor immune microenvironment.